Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Aug 15, 2023; 15(8): 1366-1383
Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1366
Published online Aug 15, 2023. doi: 10.4251/wjgo.v15.i8.1366
Figure 6 Comparison of the invasion and migration ability of gastric cancer cells after down-regulation of LINC01268.
A: The invasive ability of MGC80-3 in the sh-LINC01268 group was significantly weaker than that in the sh-negative control (sh-NC) group; B: The migration ability of MGC80-3 in the sh-LINC01268 group was significantly weaker than that in the sh-NC group; C: The invasive ability of AGS in the sh-LINC01268 group was significantly weaker than that in the sh-NC group; D: The migration ability of AGS in the sh-LINC01268 group was significantly weaker than that in the sh-NC group; E: After knocking down the expression of LINC01268 in MGC80-3, the cell migration ability was significantly weakened; F: After knocking down the expression of LINC01268 in AGS, the cell migration ability was significantly weakened. All the experiments were performed in triplicate. The results were shown as the mean ± SD. aP < 0.05, bP < 0.01, cP < 0.001. sh-NC: sh-negative control.
- Citation: Tang LH, Ye PC, Yao L, Luo YJ, Tan W, Xiang WP, Liu ZL, Tan L, Xiao JW. LINC01268 promotes epithelial-mesenchymal transition, invasion and metastasis of gastric cancer via the PI3K/Akt signaling pathway and targeting MARCKS. World J Gastrointest Oncol 2023; 15(8): 1366-1383
- URL: https://www.wjgnet.com/1948-5204/full/v15/i8/1366.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i8.1366